TAMOFEN 10 10 MG
TAMOXIFEN (TAMOXIFEN CITRATE) : 10 MG · DIN 01926624 · SANOFI-AVENTIS CANADA INC
Health Canada status: CANCELLED POST MARKET
What is TAMOFEN 10?
TAMOFEN 10 10 MG contains TAMOXIFEN (TAMOXIFEN CITRATE) : 10 MG. It is listed in the Health Canada Drug Product Database under DIN 01926624, held by SANOFI-AVENTIS CANADA INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 11-Jan-2011. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is TAMOFEN 10 used for?
TAMOFEN (tamoxifen citrate) is indicated for the adjuvant treatment of early breast cancer in women with estrogen receptor positive tumors. TAMOFEN is indicated for the treatment of women with hormone responsive locally advanced/metastatic breast cancer.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 01926624 |
|---|---|
| Brand name | TAMOFEN 10 |
| Generic / active ingredient | TAMOXIFEN (TAMOXIFEN CITRATE) : 10 MG |
| Manufacturer | SANOFI-AVENTIS CANADA INC |
| Strength | 10 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | L02BA01 TAMOXIFEN |
| AHFS class | 10:00.00 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 11-Jan-2011 |
| Original market date | 1986-12-31 00:00:00 |
How is it administered?
Usual dose: 20 to 40 mg per day in single or two divided doses. Use lowest effective dose. In early disease, recommended duration is 5 years.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store at room temperature (between 15 and 30°C) in a well closed container. Protect from light.
How is it supplied?
Plastic containers of 60 and 250 tablets; or boxes of 60 tablets in aluminium film strips (unit dose packages) for 10mg tablets. Plastic containers of 60 tablets; or boxes of 30 and 60 tablets in aluminium film strips (unit dose packages) for 20mg tablets.
Contraindications
Pregnancy; hypersensitivity to tamoxifen or any component. Contraindicated in prevention setting (not approved in Canada) for patients with history of stroke, DVT, or pulmonary embolism.
Warnings and precautions
Increased risk of uterine malignancies (endometrial cancer, uterine sarcoma), stroke, pulmonary embolism, and deep vein thrombosis. Risk of cataracts and liver changes.
What can be used instead?
Other Canadian products sharing ATC code L02BA01 TAMOXIFEN. 4 of 24 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-TAMOX TAB 10MG | 10 MG | TABLET | APOTEX INC | MARKETED | DIN 00812404 |
| APO-TAMOX TAB 20MG | 20 MG | TABLET | APOTEX INC | MARKETED | DIN 00812390 |
| TEVA-TAMOXIFEN | 10 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 00851965 |
| TEVA-TAMOXIFEN | 20 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 00851973 |
| DOM-TAMOXIFEN | 10 MG | TABLET | DOMINION PHARMACAL | CANCELLED POST MARKET | DIN 02237598 |
| DOM-TAMOXIFEN | 20 MG | TABLET | DOMINION PHARMACAL | CANCELLED PRE MARKET | DIN 02237599 |
| MYLAN-TAMOXIFEN | 10 MG | TABLET | MYLAN PHARMACEUTICALS ULC | CANCELLED POST MARKET | DIN 02088428 |
| MYLAN-TAMOXIFEN | 20 MG | TABLET | MYLAN PHARMACEUTICALS ULC | CANCELLED POST MARKET | DIN 02089858 |
| NOLVADEX TAB 10MG | 10 MG | TABLET | ASTRAZENECA CANADA INC | CANCELLED POST MARKET | DIN 02048477 |
| NOLVADEX-D TAB 20MG | 20 MG | TABLET | ASTRAZENECA CANADA INC | CANCELLED POST MARKET | DIN 02048485 |
Who else supplies TAMOXIFEN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. TAMOXIFEN appears in 93 registered pack listings across 14 markets, published on 11 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.